Investigational Drug Information for AKST4290
✉ Email this page to a colleague
What is the development status for investigational drug AKST4290?
AKST4290 is an investigational drug.
There have been 6 clinical trials for AKST4290.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 28th 2020.
The most common disease conditions in clinical trials are Macular Degeneration, Retinal Diseases, and Diabetic Retinopathy. The leading clinical trial sponsors are Alkahest, Inc. and [disabled in preview].
Summary for AKST4290
| US Patents | 0 |
| International Patents | 83 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-01-28) |
| Vendors | 17 |
Recent Clinical Trials for AKST4290
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI) | Alkahest, Inc. | Phase 2 |
| A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid | Alkahest, Inc. | Phase 2 |
| A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD | Alkahest, Inc. | Phase 2 |
Clinical Trial Summary for AKST4290
Top disease conditions for AKST4290
Top clinical trial sponsors for AKST4290
US Patents for AKST4290
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AKST4290
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AKST4290 | African Regional IP Organization (ARIPO) | AP2989 | 2029-04-08 | ⤷ Sign Up |
| AKST4290 | Argentina | AR076228 | 2029-04-08 | ⤷ Sign Up |
| AKST4290 | Australia | AU2010233849 | 2029-04-08 | ⤷ Sign Up |
| AKST4290 | Brazil | BR122019017002 | 2029-04-08 | ⤷ Sign Up |
| AKST4290 | Brazil | BRPI1013821 | 2029-04-08 | ⤷ Sign Up |
| AKST4290 | Canada | CA2753151 | 2029-04-08 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
